



## Clinical trial results:

### A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension

#### Summary

EudraCT number	2015-003631-34
Trial protocol	BE ES CZ FR DK IT
Global end of trial date	26 January 2021

#### Results information

Result version number	v1
This version publication date	10 February 2022
First version publication date	10 February 2022

#### Trial information

##### Trial identification

Sponsor protocol code	192024-095
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02636946
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Allergan Limited
Sponsor organisation address	Marlow International The Parkway, Marlow Buckinghamshire, United Kingdom, SL7 1YL
Public contact	Global Medical Services, AbbVie, AbbVie Deutschland GmbH & Co. KG, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>
Scientific contact	Global Medical Services, AbbVie, AbbVie Deutschland GmbH & Co. KG, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 January 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 January 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 February 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	Spain: 2
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Russian Federation: 6
Country: Number of subjects enrolled	Singapore: 3
Country: Number of subjects enrolled	Thailand: 2
Country: Number of subjects enrolled	United States: 115
Worldwide total number of subjects	144
EEA total number of subjects	18

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	91
From 65 to 84 years	53
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 144 participants were randomised with 72 participants in each treatment group. Out of them 142 participants were treated. The primary eye was defined as the eye with the higher intraocular pressure (IOP) at Baseline. If both the eyes were the same, the right eye was used as the primary eye. The contralateral eye is the other eye.

### Period 1

Period 1 title	Cycle 1 (Day 1 to Week 15)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind <sup>[1]</sup>
Roles blinded	Subject, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)

Arm description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Arm type	Active comparator
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use

Dosage and administration details:

Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use

Dosage and administration details:

Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use

Dosage and administration details:

Selective Laser Trabeculoplasty administered on Day 1.

Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Sham Selective Laser Trabeculoplasty administered on Day 1.	
<b>Arm title</b>	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)

**Arm description:**

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Arm type	Experimental
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use

**Dosage and administration details:**

Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use

**Dosage and administration details:**

Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use

**Dosage and administration details:**

Selective Laser Trabeculoplasty administered on Day 1.

Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use

**Dosage and administration details:**

Sham Selective Laser Trabeculoplasty administered on Day 1.

**Notes:**

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The Investigator was not blinded.

Number of subjects in period 1	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
Started	72	72
Received Treatment in Either Eye	72	70
Completed	71	67
Not completed	1	5
Withdrawal of Consent	-	1
Randomized but not Treated	-	2
Protocol Violation	-	1
Lost to follow-up	1	-
Reason not Specified	-	1

## Period 2

Period 2 title	Cycle 2 (Week 16 to Week 31)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind <sup>[2]</sup>
Roles blinded	Subject, Carer, Assessor

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)

### Arm description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Arm type	Active comparator
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use

### Dosage and administration details:

Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use

Dosage and administration details:	
Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Selective Laser Trabeculoplasty administered on Day 1.	
Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Sham Selective Laser Trabeculoplasty administered on Day 1.	
<b>Arm title</b>	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
Arm description:	
Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.	
Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.	
Arm type	Experimental
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use
Dosage and administration details:	
Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use
Dosage and administration details:	
Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Selective Laser Trabeculoplasty administered on Day 1.	
Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use

Dosage and administration details:

Sham Selective Laser Trabeculoplasty administered on Day 1.

Notes:

[2] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The Investigator was not blinded.

Number of subjects in period 2 <sup>[3]</sup>	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
Started	65	62
Completed	63	61
Not completed	2	1
Adverse Event	2	1

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Started=received administration (Sham or Bimatoprost SR) in the cycle

### Period 3

Period 3 title	Cycle 3 (Week 32 to Week 52)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind <sup>[4]</sup>
Roles blinded	Subject, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
Arm title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)

Arm description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Arm type	Active comparator
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use

Dosage and administration details:

Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).

Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	



Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use
Dosage and administration details:	
Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Selective Laser Trabeculoplasty administered on Day 1.	
Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Sham Selective Laser Trabeculoplasty administered on Day 1.	
<b>Arm title</b>	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
Arm description:	
Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.	
Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.	
Arm type	Experimental
Investigational medicinal product name	Bimatoprost SR
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Implant in pre-filled syringe
Routes of administration	Ophthalmic use
Dosage and administration details:	
Up to three Bimatoprost SR 15 micrograms (µg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 µg administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Sham Bimatoprost SR: Applicator Without Needle
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in needle-free injector
Routes of administration	Ophthalmic use
Dosage and administration details:	
Up to three Sham Bimatoprost SR [applicator without needle] administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).	
Investigational medicinal product name	Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use
Dosage and administration details:	
Selective Laser Trabeculoplasty administered on Day 1.	

Investigational medicinal product name	Sham Selective Laser Trabeculoplasty
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pharmaceutical dose form not applicable
Routes of administration	Ophthalmic use

Dosage and administration details:

Sham Selective Laser Trabeculoplasty administered on Day 1.

Notes:

[4] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The Investigator was not blinded.

<b>Number of subjects in period 3<sup>[5]</sup></b>	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
Started	17	16
Completed	17	16

Notes:

[5] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Started=received administration (Sham or Bimatoprost SR) in the cycle

## Baseline characteristics

### Reporting groups

Reporting group title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Reporting group title	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Reporting group values	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)	Total
Number of subjects	72	72	144
Age categorical Units: Subjects			
Adults (18-64 years)	53	38	91
From 65-84 years	19	34	53
Age continuous Units: years			
arithmetic mean	57.9	62.1	
standard deviation	± 10.2	± 11.4	-
Gender categorical Units: Subjects			
Female	28	39	67
Male	44	33	77
Race Units: Subjects			
White	53	59	112
Black or African American	12	9	21
Asian	5	3	8
Not Reported	2	1	3
Ethnicity Units: Subjects			
Hispanic	11	7	18
Non-Hispanic	61	64	125
Not Reported	0	1	1

## End points

### End points reporting groups

Reporting group title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Reporting group title	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Reporting group title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Reporting group title	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Reporting group title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Reporting group title	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under

Subject analysis set title	Selective Laser Trabeculoplasty
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

SLT administered on Day 1.

Participants' primary eyes from 'SLT (Primary Eye) / Bim SR 15 ug (Contralateral Eye)' arm and contralateral eyes from 'Bim SR 15 ug (Primary Eye) / SLT (Contralateral Eye)' arm were combined for outcome measure analyses.

Subject analysis set title	Bim SR 15 µg
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Participants' contralateral eyes from 'SLT (Primary Eye) / Bim SR 15 ug (Contralateral Eye)' arm and primary eyes from 'Bim SR 15 ug (Primary Eye) / SLT (Contralateral Eye)' arm were combined for outcome measure analyses.

### Primary: Change From Baseline in IOP at Week 4

End point title	Change From Baseline in IOP at Week 4
-----------------	---------------------------------------

End point description:

IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A mixed-effects model with repeated measures (MMRM) was used for analyses. Modified Intent-to-Treat (mITT) Population was defined based in the Intent-to-Treat (ITT) population but excluded participants who did not receive the second implant after implementation of Amendment 3. Overall number analysed are number of participants and eyes with data available for analyses.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (prior to treatment) to Week 4

End point values	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	131	135		
Units: mmHg				
least squares mean (standard error)	-6.28 (± 0.30)	-6.98 (± 0.29)		

### Statistical analyses

Statistical analysis title	Change from Baseline at Week 4
----------------------------	--------------------------------

Statistical analysis description:

The null hypothesis was that bimatoprost SR 15 µg was to be declared non-inferior to SLT if the upper limit of the 95% CI was  $\leq 1.5$  mmHg at all scheduled visits (Weeks 4, 12, and 24).

Comparison groups	Selective Laser Trabeculoplasty v Bim SR 15 µg
-------------------	--

Number of subjects included in analysis	266
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
P-value	= 0.0166
Method	MMRM
Parameter estimate	Least-squares Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.28
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	0.29

Notes:

[1] - MMRM was used for IOP change from baseline. The model includes IOP change from baseline as the response variable and treatment, visit, eye, baseline IOP, treatment-by-baseline, treatment-by-eye, treatment-by-visit, visit-by-eye interactions as covariates. A Kronecker product of unstructured covariance matrix for study visit and compound symmetry covariance matrix for between eye correlation was used in the analysis.

### Primary: Change From Baseline in IOP at Week 12

End point title	Change From Baseline in IOP at Week 12
End point description:	
IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A MMRM was used for analyses. mITT Population was defined based in the ITT population but excluded participants who did not receive the second implant after implementation of Amendment 3. Overall number analysed are number of participants and eyes with data available for analyses.	
End point type	Primary
End point timeframe:	
Baseline (prior to treatment) to Week 12	

End point values	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	122	128		
Units: mmHg				
least squares mean (standard error)	-6.28 (± 0.29)	-6.81 (± 0.29)		

### Statistical analyses

Statistical analysis title	Change from Baseline at Week 12
Statistical analysis description:	
The null hypothesis was that bimatoprost SR 15 µg was to be declared non-inferior to SLT if the upper limit of the 95% CI was ≤ 1.5 mmHg at all scheduled visits (Weeks 4, 12, and 24).	
Comparison groups	Selective Laser Trabeculoplasty v Bim SR 15 µg

Number of subjects included in analysis	250
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[2]</sup>
P-value	= 0.0735
Method	MMRM
Parameter estimate	Least-squares Mean Difference
Point estimate	-0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.09
upper limit	0.05
Variability estimate	Standard error of the mean
Dispersion value	0.29

Notes:

[2] - MMRM was used for IOP change from baseline. The model includes IOP change from baseline as the response variable and treatment, visit, eye, baseline IOP, treatment-by-baseline, treatment-by-eye, treatment-by-visit, visit-by-eye interactions as covariates. A Kronecker product of unstructured covariance matrix for study visit and compound symmetry covariance matrix for between eye correlation was used in the analysis.

### Primary: Change From Baseline in Intraocular Pressure (IOP) at Week 24

End point title	Change From Baseline in Intraocular Pressure (IOP) at Week 24
-----------------	---

End point description:

IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A MMRM was used for analyses. mITT Population was defined based in the ITT population but excluded participants who did not receive the second implant after implementation of Amendment 3. Overall number analyzed are number of participants and eyes with data available for analyses.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (prior to treatment) to Week 24

End point values	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	117	126		
Units: mmHg				
least squares mean (standard error)	-6.34 (± 0.29)	-6.59 (± 0.29)		

### Statistical analyses

Statistical analysis title	Change from Baseline at Week 24
----------------------------	---------------------------------

Statistical analysis description:

The null hypothesis was that bimatoprost SR 15 µg was to be declared non-inferior to SLT if the upper limit of the 95% confidence interval (CI) was  $\leq 1.5$  mmHg at all scheduled visits (Weeks 4, 12, and 24).

Comparison groups	Selective Laser Trabeculoplasty v Bim SR 15 µg
-------------------	--

Number of subjects included in analysis	243
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[3]</sup>
P-value	= 0.3928
Method	MMRM
Parameter estimate	Least-squares Mean Difference
Point estimate	-0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.81
upper limit	0.32
Variability estimate	Standard error of the mean
Dispersion value	0.29

Notes:

[3] - MMRM was used for IOP change from baseline. The model includes IOP change from baseline as the response variable and treatment, visit, eye, baseline IOP, treatment-by-baseline, treatment-by-eye, treatment-by-visit, visit-by-eye interactions as covariates. A Kronecker product of unstructured covariance matrix for study visit and compound symmetry covariance matrix for between eye correlation was used in the analysis.

## Secondary: Change From Baseline in IOP at Weeks 8, 15, and 20

End point title	Change From Baseline in IOP at Weeks 8, 15, and 20
End point description:	
IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. ITT Population was defined as all randomized participants. n=number analysed is the number of participants and eyes analysed at the given timepoint.	
End point type	Secondary
End point timeframe:	
Baseline (prior to treatment) to Weeks 8, 15 and 20	

End point values	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	144	144		
Units: mmHg				
arithmetic mean (standard deviation)				
Change from Baseline at Week 8 (n=133, 137)	-6.65 (± 3.10)	-7.09 (± 2.93)		
Change from Baseline at Week 15 (n=126, 133)	-6.14 (± 3.47)	-5.36 (± 3.73)		
Change from Baseline at Week 20 (n=8, 7)	-5.06 (± 3.33)	-4.29 (± 1.93)		

## Statistical analyses

No statistical analyses for this end point



**Secondary: Time to Initial Use of Nonstudy IOP-lowering Treatment as Determined by the Investigator**

End point title	Time to Initial Use of Nonstudy IOP-lowering Treatment as Determined by the Investigator
-----------------	--

End point description:

Median time in days from first treatment to the initial use of non-study IOP-lowering treatment. ITT Population was defined as all randomized participants. Overall number analyzed are number of participants and eyes with data available for analyses. 99999 denotes the upper limit of 95% confidence interval was not estimable due to the low number of participants with events.

End point type	Secondary
----------------	-----------

End point timeframe:

First treatment to end of study (up to 525 days)

<b>End point values</b>	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	142	141		
Units: days				
median (confidence interval 95%)	410 (392.0 to 99999)	446 (407.0 to 99999)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of Participants With Eyes Achieving a  $\geq 20\%$  Reduction in IOP**

End point title	Percentage of Participants With Eyes Achieving a $\geq 20\%$ Reduction in IOP
-----------------	---

End point description:

IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. The participants who did not continue in the subsequent cycle were followed up to Week 52 in Cycle 1, Week 36 in Cycle 2, and Week 20 in Cycle 3. ITT Population was defined as all randomized participants. n=number analysed and is number of participants and eyes analysed at the given timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (prior to treatment) to Cycle 1: Day 2, Weeks 4, 8, 12, 15, 20, 24, 28, 31, 36, 40, 44, 47, 52; Cycle 2:Day 2, Weeks 4, 8, 12, 15, 20, 24, 28, 31, 36; Cycle 3: Day 2, Weeks 4, 8, 15, 20

<b>End point values</b>	Selective Laser Trabeculoplasty	Bim SR 15 µg		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	144	144		
Units: percentage of participants				
number (not applicable)				
Cycle 1 Day 2 (n= 137, 137)	60.6	92.7		

Cycle 1 Week 4 (n= 141, 141)	70.2	78.0		
Cycle 1 Week 8 (n= 140, 140)	72.9	80.0		
Cycle 1 Week 12 (n= 137, 137)	67.9	75.2		
Cycle 1 Week 15 (n= 134, 134)	67.2	64.2		
Cycle 1 Week 20 (n= 10, 10)	50.0	40.0		
Cycle 1 Week 24 (n= 11, 11)	81.8	45.5		
Cycle 1 Week 28 (n= 11, 11)	63.6	45.5		
Cycle 1 Week 31 (n= 5, 5)	100.0	40.0		
Cycle 1 Week 36 (n= 11, 11)	72.7	72.7		
Cycle 1 Week 40 (n= 11, 11)	54.5	54.5		
Cycle 1 Week 44 (n= 11, 11)	81.8	45.5		
Cycle 1 Week 47 (n= 11, 11)	72.7	54.5		
Cycle 1 Week 52 (n= 11, 11)	81.8	81.8		
Cycle 2 Day 2 (n= 124, 124)	70.2	89.5		
Cycle 2 Week 4 (n= 125, 125)	68.8	75.2		
Cycle 2 Week 8 (n= 124, 124)	68.5	71.0		
Cycle 2 Week 12 (n= 118, 118)	72.0	65.3		
Cycle 2 Week 15 (n= 98, 98)	69.4	64.3		
Cycle 2 Week 20 (n= 91, 91)	76.9	64.8		
Cycle 2 Week 24 (n= 87, 87)	64.4	71.3		
Cycle 2 Week 28 (n= 85, 85)	76.5	74.1		
Cycle 2 Week 31 (n= 86, 86)	76.7	74.4		
Cycle 2 Week 36 (n= 91, 91)	79.1	67.0		
Cycle 3 Day 2 (n= 33, 33)	75.8	90.9		
Cycle 3 Week 4 (n= 31, 31)	74.2	71.0		
Cycle 3 Week 8 (n= 32, 32)	75.0	59.4		
Cycle 3 Week 15 (n= 30, 30)	70.0	43.3		
Cycle 3 Week 20 (n= 33, 33)	69.7	39.4		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

First treatment to end of study (up to 525 days)

Adverse event reporting additional description:

All-cause Mortality:ITT Population=all randomized participants.Serious/Other AEs:Safety Population=all treated participants;data collected,presented as randomized.Ocular AEs(Eye Disorders)collected and reported for each eye(primary/contralateral)separately.AE footnotes=number of AEs in primary and contralateral eye.A participant could have≥1events.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.

Reporting group title	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)
-----------------------	--

Reporting group description:

Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 µg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Serious adverse events	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 72 (15.28%)	6 / 70 (8.57%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			

subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Quadrantanopia	Additional description: 1 adverse event occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=0, Contralateral Eye=1).		
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Corneal endothelial cell loss	Additional description: 4 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=0, Contralateral Eye=4); 1 adverse event occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=1, Contralateral Eye=0).		

subjects affected / exposed	4 / 72 (5.56%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	4 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract	Additional description: 1 adverse event occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=0, Contralateral Eye=1).		
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal oedema	Additional description: 2 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=2, Contralateral Eye=0).		
subjects affected / exposed	0 / 72 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haematoma			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haemorrhage			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			

subjects affected / exposed	0 / 72 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	1 / 72 (1.39%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)	Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	56 / 72 (77.78%)	44 / 70 (62.86%)	
Investigations			
Intraocular pressure increased	Additional description: 18 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=8, Contralateral Eye=10); 12 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=6, Contralateral Eye=6).		
subjects affected / exposed	13 / 72 (18.06%)	7 / 70 (10.00%)	
occurrences (all)	21	13	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 72 (2.78%)	6 / 70 (8.57%)	
occurrences (all)	2	6	
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 72 (4.17%)	4 / 70 (5.71%)	
occurrences (all)	5	5	
Eye disorders			
Conjunctival hyperaemia	Additional description: 48 adverse events occurred in SLT (Primary Eye)/Bim SR 15 µg (Contralateral Eye) Arm:(Primary Eye=20,Contralateral Eye=28);27 adverse events occurred in Bim SR 15 µg(Primary Eye)/SLT (Contralateral Eye) Arm (Primary Eye=19, Contralateral Eye=8).		
subjects affected / exposed	30 / 72 (41.67%)	19 / 70 (27.14%)	
occurrences (all)	79	36	
Corneal endothelial cell loss	Additional description: 11 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=1, Contralateral Eye=10); 4 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=3, Contralateral Eye=1).		

subjects affected / exposed	11 / 72 (15.28%)	4 / 70 (5.71%)	
occurrences (all)	12	4	
Punctate keratitis	Additional description: 18 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=8, Contralateral Eye=10); 14 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=8, Contralateral Eye=6).		
subjects affected / exposed	10 / 72 (13.89%)	8 / 70 (11.43%)	
occurrences (all)	20	21	
Conjunctival haemorrhage	Additional description: 8 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=1, Contralateral Eye=7); 7 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=5, Contralateral Eye=2).		
subjects affected / exposed	7 / 72 (9.72%)	5 / 70 (7.14%)	
occurrences (all)	9	9	
Corneal oedema	Additional description: 6 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=1, Contralateral Eye=5); 9 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=8, Contralateral Eye=1).		
subjects affected / exposed	6 / 72 (8.33%)	9 / 70 (12.86%)	
occurrences (all)	7	9	
Photophobia	Additional description: 8 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=2, Contralateral Eye=6); 6 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=4, Contralateral Eye=2).		
subjects affected / exposed	6 / 72 (8.33%)	4 / 70 (5.71%)	
occurrences (all)	12	10	
Eye irritation	Additional description: 10 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=4, Contralateral Eye=6); 5 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=3, Contralateral Eye=2).		
subjects affected / exposed	6 / 72 (8.33%)	3 / 70 (4.29%)	
occurrences (all)	14	7	
Eye pain	Additional description: 6 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=4, Contralateral Eye=2); 10 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=7, Contralateral Eye=3).		
subjects affected / exposed	5 / 72 (6.94%)	9 / 70 (12.86%)	
occurrences (all)	6	11	
Dry eye	Additional description: 8 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=4, Contralateral Eye=4); 4 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=3, Contralateral Eye=1).		
subjects affected / exposed	5 / 72 (6.94%)	3 / 70 (4.29%)	
occurrences (all)	11	4	
Anterior chamber cell	Additional description: 5 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=1, Contralateral Eye=4); 3 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=2, Contralateral Eye=1).		
subjects affected / exposed	4 / 72 (5.56%)	3 / 70 (4.29%)	
occurrences (all)	6	3	
Foreign body sensation in eyes	Additional description: 5 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=1, Contralateral Eye=4); 3 adverse		

events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=3, Contralateral Eye=0).			
subjects affected / exposed	4 / 72 (5.56%)	3 / 70 (4.29%)	
occurrences (all)	6	3	
Corneal opacity			
subjects affected / exposed	4 / 72 (5.56%)	0 / 70 (0.00%)	
occurrences (all)	4	0	
Infections and infestations			
Conjunctivitis			
Additional description: 4 adverse events occurred in SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) Arm: (Primary Eye=0, Contralateral Eye=4); 2 adverse events occurred in Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Arm (Primary Eye=1, Contralateral Eye=1).			
subjects affected / exposed	4 / 72 (5.56%)	1 / 70 (1.43%)	
occurrences (all)	5	2	
Sinusitis			
subjects affected / exposed	1 / 72 (1.39%)	4 / 70 (5.71%)	
occurrences (all)	1	6	
Metabolism and nutrition disorders			
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 72 (0.00%)	4 / 70 (5.71%)	
occurrences (all)	0	4	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 April 2017	The following changes were implemented with Amendment 1: Changed requirement for additional biomicroscopy and IOP measurements on Day 1 for participants with sickle-cell disease to be optional. Updated study status. Updated information from completed studies. Updated the approximate number of sites. Modified the eligibility criteria. For clarification purposes, revised to use generic terminology rather than brand names, which may not be identical in all study locations. Revised storage conditions of the product. Corrected errors in the original protocol. Visit window text was revised for clarification. Reordered some study procedures and clarified which procedures must be performed in the order shown to provide additional flexibility to sites and participants.
28 September 2018	The following changes were implemented with Amendment 2: Reduced the number of administration cycles from 3 to 2. Added new schedule for all participants for Week 36 through Week 52/Exit and removed these visits from the schedule for the third treatment cycle. Specified number of administration cycles for participants enrolled in each stage. Specified that visits associated with the third treatment cycle are for participants who reached Week 32 prior to implementation of Amendment 2 only. Extended safety follow-up period for participants who received nonstudy IOP-lowering medication in both eyes or did not complete an administration visit. Specified analysis populations, and analyses for Stages 1 and 2. Increased sample size so that approximately 160 participants would be enrolled in the study.
27 March 2020	The following changes were implemented with Amendment 3: Updated the protocol to reflect that participants who were enrolled and had not yet reached Week 16 would not receive Cycle 2 administration and no additional administrations of the Bimatoprost SR 15 µg dose would be given. Therefore, the Week 16 would not be required for these participants and they would continue to be followed at the scheduled follow-up visits through Week 52/Exit. Revised statistical methods. Added Rho-kinase inhibitors to the list of medications requiring washout.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported